Cancer Research UK backs Hummingbird’s cancer treatment development

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags: Cancer research uk, Cancer, Hummingbird Bioscience, funding

Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.

Hummingbird Bioscience, a biotechnology company developing cancer therapeutics, announced a partnership with Cancer Research UK charity to move its cancer treatment HMBD-001 into Phase I clinical trials.

Under the agreement, Cancer Research UK’s Centre for Drug Development will fund the program, manufacture the clinical grade antibody, and conduct the trial under the charity organization’s clinical development partnerships scheme.

HMBD-001, which was developed using Hummingbird’s rational antibody discovery platform, targets the HER3 receptor, obstructing it from binding to other cancer-associated proteins.

It is being investigated as a treatment for multiple solid tumours, including breast, gastric, pancreatic, ovarian, and lung cancers. According to Cancer Research UK, the treatment could also be effective against drug resistant cancers, as it ‘completely turns off’ the HER3 signal responsible for cancer cells’ growth.

“For many people with cancer, targeted treatments can work in the short term, but drug resistance sometimes leads to the eventual return of their tumour,” ​Nigel Blackburn, Cancer Research UK’s director of drug development, said in a statement, adding that HMBD-001 has the potential to overcome the key mechanism of drug resistance.

Following the completion of Phase I trials, Hummingbird will have the option to acquire the rights to the clinical trial results and further advance the program, otherwise Cancer Research UK will have the right to take the program forward in all indications.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars